Can a fixed-ratio combination of insulin degludec and liraglutide help Type 2 diabetes patients to optimize glycemic control across the day?

Expert Review of Clinical Pharmacology

Volumn 8, Issue 2, 2015, Pages 179-188

  Simpson, Richard ^a   King, Allen ^b  

^a MONASH UNIVERSITY   (Australia)

^b Diabetes Care Center   (United States)

Author keywords

basal insulin; combination therapy; DUAL study; incretin therapy; insulin degludec; liraglutide; Type 2 diabetes

Indexed keywords

GLUCOSE; INSULIN; INSULIN DEGLUDEC PLUS LIRAGLUTIDE; ANTIDIABETIC AGENT; DRUG COMBINATION; GLUCAGON LIKE PEPTIDE 1; GLUCOSE BLOOD LEVEL; INSULIN DEGLUDEC; LIRAGLUTIDE; LONG ACTING INSULIN;

DIABETIC PATIENT; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; THERAPY EFFECT; WEIGHT; WEIGHT GAIN; ANALOGS AND DERIVATIVES; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; DRUG EFFECTS; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG COMBINATIONS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, LONG-ACTING; TREATMENT OUTCOME;

EID: 84923324208     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2015.1017562     Document Type: Review

References (39)

1. International Diabetes Federation. Last updated 2012. Diabetes Atlas Update 2012. Available from: www.idf.org/sites/default/ files/attachments/ 5E-IDFAtlasPoster-2012-EN.pdf? utm-medium=email&utm-campaign=IDF %20Diabetes%20Atlas%202012% 20Update&utm-content=IDF%20Diabetes %20Atlas%202012%20Update+Preview +CID-720a5262162f1f585ba9 fc8ca39fef30&utm-source=campaign monitor&utm-term=English [Last accessed on June 2014]
2. WHO Fact sheet. Available from: www. who.int/mediacentre/factsheets/fs312/en/ [Last accessed on June 2014]
3. Hemmingsen B, Lund SS, Gluud C, et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev 2013;11:CD008143
4. Hanefeld M, Duetting E, Bramlage P. Cardiac implications of hypoglycaemia in patients with diabetes - a systematic review. Cardiovasc Diabetol 2013;12:135
5. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35(6):1364-79
6. Vora J. Combining incretin-based therapies with insulin: realizing the potential in type 2 diabetes. Diabetes Care 2013; 36(Suppl 2):S226-32
7. Leiter LA, Ceriello A, Davidson JA, et al. Postprandial glucose regulation: new data and new implications. Clin Ther 2005; 27(Suppl B):S42-56
8. Blak BT, Smith HT, Hards M, et al. Optimization of insulin therapy in patients with type 2 diabetes mellitus: beyond basal insulin. Diabet Med 2012;29(7):e13-20
9. Curtis B, Lage MJ. Glycemic control among patients with type 2 diabetes who initiate basal insulin: a retrospective cohort study. J Med Econ 2014;17(1):21-31
10. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med 2012;29(5):682-9
11. Cuddihy RM, Philis-Tsimikas A, Nazeri A. Type 2 diabetes care and insulin intensification: is a more multidisciplinary approach needed? Results from the MODIFY survey. Diabetes Educ 2011; 37(1):111-23
12. Kunt T, Snoek FJ. Barriers to insulin initiation and intensification and how to overcome them. Int J Clin Pract Suppl 2009;164:6-10
13. Polinski JM, Connolly JG, Curtis BH, et al. Patterns and trends in insulin intensification among patients with type 2 diabetes: a systematic review. Prim Care Diabetes 2014;8(2):101-9
14. Nauck MA, Kleine N, Orskov C, et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulindependent) diabetic patients. Diabetologia 1993;36(8):741-4
15. Nauck MA, Niedereichholz U, Ettler R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 1997;273(5 Pt 1):E981-8
16. Holst JJ. Incretin hormones and the satiation signal. Int J Obes 2013;37(9): 1161-8
17. Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986;29(1):46-52
18. Lund A, Knop FK, Vilsbøll T. Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities. Eur J Intern Med 2014;25:407-14
19. Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in Basal insulin treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2011;154(2):103-12
20. DeVries JH, Bain SC, Rodbard HW, et al. Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets. Diabetes Care 2012;35(7):1446-54
21. Ahrén B. Insulin plus incretin: a glucose-lowering strategy for type 2-diabetes. World J Diabetes 2014; 5(1):40-51
22. Jonassen I, Havelund S, Hoeg-Jensen T, et al. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res 2012;29(8):2104-14
23. Gough SC, Harris S, Woo V, Davies M. Insulin degludec: overview of a novel ultra long-acting basal insulin. Diabetes Obes Metab 2013;15(4):301-9
24. Rigato M, Fadini GP. Comparative effectiveness of liraglutide in the treatment of type 2 diabetes. Diabetes Metab Syndr Obes 2014;7:107-20
25. Ratner RE, Gough SC, Mathieu C, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab 2013;15(2):175-84
26. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374(9683):39-47
27. Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet 2013;81(9861):117-24
28. Kapitza C, Forst T, Coester HV, et al. Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin. Diabetes Obes Metab 2013;15(7):642-9
29. Dungan KM, Povedano ST, Forst T, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet 2014; 384(9951):1349-57
30. Mathieu C, Rodbard HW, Cariou B, et al. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON). Diabetes Obes Metab 2014;16(7):636-44
31. Gough SC, Bode B, Woo V, et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol 2014;2(11):885-93
32. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373(9662):473-81
33. Marre M, Shaw J, Brändle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26:268-78
34. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009;32(1):84-90
35. Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009;52(10): 2046-55
36. Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009;32(7): 1224-30
37. Pratley RE, Nauck M, Bailey T, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010;375(9724): 1447-56
38. Gough SCL, Buse JB, Woo VC, et al. One-year efficacy and safety of IDegLira in patients with type 2 diabetes. Diabetes 2014;63(Suppl 1):A17:Abstract 65-OR
39. Buse JB, Vilsbøll T, Thurman J, et al. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira). Diabetes Care 2014; 37(11):2926-33